Structure Therapeutics (GPCR) Depreciation & Amortization (CF) (2022 - 2026)
Quarterly Depreciation & Amortization (CF) rose 110.22% to $576000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Mar 2026, up 56.61% year-over-year, with the annual reading at $1.3 million for FY2025, 34.38% up from the prior year.
Structure Therapeutics' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $576000.0 for Q1 2026.
- Depreciation & Amortization (CF) came in at $576000.0 for Q1 2026, up from $412000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $576000.0 in Q1 2026 to a low of $59000.0 in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $222000.0 (2024), against an average of $204294.1.
- Year-over-year, Depreciation & Amortization (CF) changed 0.0% in 2023 and then skyrocketed 279.17% in 2024.
- Structure Therapeutics' Depreciation & Amortization (CF) stood at $72000.0 in 2022, then changed by 0.0% to $72000.0 in 2023, then surged by 279.17% to $273000.0 in 2024, then skyrocketed by 50.92% to $412000.0 in 2025, then soared by 39.81% to $576000.0 in 2026.
- Per Business Quant, the three most recent readings for GPCR's Depreciation & Amortization (CF) are $576000.0 (Q1 2026), $412000.0 (Q4 2025), and $356000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 123.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | 576,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 576,000.00 |
| Mar 31, 2026 | 576,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Jun 30, 2024 | 232,000.00 |
| Jun 30, 2024 | 232,000.00 |
| Mar 31, 2024 | 222,000.00 |
| Mar 31, 2024 | 222,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Jun 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 74,000.00 |
| Mar 31, 2023 | 70,000.00 |
| Mar 31, 2023 | 70,000.00 |
| Dec 31, 2022 | 72,000.00 |
| Dec 31, 2022 | 72,000.00 |
| Sep 30, 2022 | 76,000.00 |
| Sep 30, 2022 | 76,000.00 |
| Jun 30, 2022 | 59,000.00 |
| Jun 30, 2022 | 59,000.00 |
| Mar 31, 2022 | 70,000.00 |
| Mar 31, 2022 | 70,000.00 |